Leslie Wilmet Nelson

Dr. Leslie Wilmet Nelson

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
LNLeslie Wilmet Nelson
Leslie Wilmet Nelson
DRDarington Richardson
Darington Richardson
NCNiraj R. Chavan
Niraj R. Chavan
HKHarit Kapoor
Harit Kapoor
ZSZachary D. Stanley
Zachary D. Stanley
AKAman Khurana
Aman Khurana

20 June 2026 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
WFWilfred Furtado
Wilfred Furtado
AGAmanda Gibson
Amanda Gibson
LNLeslie Wilmet Nelson
Leslie Wilmet Nelson
AKAman Khurana
Aman Khurana
JLJames Lee
James Lee
AAAndres Ayoob
Andres Ayoob

25 August 2021
Verified
Standard
Closed access
LNLeslie Wilmet Nelson
Leslie Wilmet Nelson
MFMba Eric M. Freeman
Mba Eric M. Freeman
AKAman Khurana
Aman Khurana
RSNA Case Collection is a collection of peer-reviewed radiology cases.

21 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DRDaniel F. Roadman
Daniel F. Roadman
DSDaniel David Shapiro
Daniel David Shapiro
ADArighno Das
Arighno Das
LNLeslie Wilmet Nelson
Leslie Wilmet Nelson
PLPaz Lotan
Paz Lotan
EAE Jason Abel
E Jason Abel
Background/Objectives: Percutaneous microwave (MW) ablation is a nephron sparing treatment for localized renal cell carcinoma (RCC). We compared perioperative, renal functional, and oncologic outcomes for clinical stage 1 RCC treated with MW ablation, PN, or RN. Methods: Adults with clinical T1 kidney masses treated with MW ablation, PN, or RN from 2001–2025 were identified. Outcomes included: 90-day overall and major complication rate, 30-day readmission rate, length of hospital stay (LOS), change in renal function, local recurrence-free survival (LRFS), metastasis-free survival (MFS), and cancer-specific survival (CSS). Univariable and multivariable analyses evaluated outcomes adjusted for confounders. Results: A total of 2201 patients with renal masses ≤ 7 cm and no evidence of locally advanced or metastatic disease were treated with MW ablation (708), PN (729), or RN (764). MW ablation patients were older and more comorbid compared to both PN/RN, whereas RN patients had larger, higher-grade tumors. Ninety-day overall complications were lowest after MW ablation (8.9% vs. 20.3% PN, p < 0.001 and 8.9% vs. 19.9% RN, p < 0.001). LOS was shortest after MW ablation (median 1 day vs. 3 days PN/RN, p < 0.001 for each). Six-month eGFR decline was similar after MW ablation and PN (−5.2% and −4.7%, p = 0.84) but greater after RN (−32.9%, p < 0.001). Local recurrences were more common with MW ablation, with five-year LRFS 96.4% versus 99.7% for PN (p < 0.001). Five-year MFS (99.5% vs. 99.7%, p = 0.24) and CSS (99.3% vs. 99.7%, p = 0.71) did not differ between MW ablation and PN. Conclusions: Percutaneous MW ablation has comparable metastasis free and cancer specific survival with lower perioperative morbidity and comparable renal preservation to PN, despite worse baseline comorbidity and renal function. These findings support MW ablation as an effective nephron-sparing option for appropriately selected patients with clinical T1 RCC when performed at an experienced center.